Gestational diabetes mellitus (GDM) is a common complication of pregnancy in which women without previously diagnosed diabetes develop chronic hyperglycemia during pregnancy. It is associated with a number of maternal and fetal/neonatal complications. The role of the adipokines retinol binding protein-4, resistin and nesfatin-1 in the development of GDM is relatively poorly understood, but their role in glucose metabolism is suspected and their use as early markers to predict the development of GDM is being sought. The aim of study was to determine the correlation between the levels of selected adipokines (retinol binding protein-4, resistin, nesfatin-1) in women with gestational diabetes mellitus (GDM) and healthy pregnant women and to compare their levels with other clinical and biochemical parameters. Patients with GDM had significantly higher BMI (28.4±4.5 vs. 24.6±4 kg/m2), total cholesterol (6±1.3 vs. 5.3±1.4 mmol/l) and triacylglycerols (1.9±0.8 vs. 1.4±0.7 mmol/l) than women in the control group. RBP4 confirms the significant difference between the groups, it is higher in the control group of healthy pregnant women. The adipokines resistin and nesfatin-1 show no differences between the control and GDM groups, but their ratios with BMI, cholesterol and triacylglycerols, resistin shows elevated levels in the control group. In women with GDM, RBP4 was significantly positively correlated with C-peptide and negatively correlated with total, LDL, and non-HDL cholesterol. Resistin was also negatively correlated with total, LDL, HDL, and non-HDL cholesterol. Nesfatin-1 was only moderately positively correlated with glycated hemoglobin (HbA1C) and fasting glycemia. There is ambiguity in the results of previous studies on the levels of the investigated adipokines in pregnant women with GDM and the interpretation depends on many factors. Keywords: Gestational diabetes, Adipokines, Retinol-binding protein 4, Resistin, Nesfatin-1.

• MeSH
• adipokiny krev   MeSH
• biologické markery * krev   MeSH
• DNA vazebné proteiny krev   MeSH
• dospělí MeSH
• gestační diabetes * krev   diagnóza   MeSH
• krevní glukóza metabolismus   MeSH
• lidé MeSH
• nukleobindiny * krev   MeSH
• plazmatické proteiny vázající retinol * metabolismus   analýza   MeSH
• proteiny nervové tkáně krev   MeSH
• proteiny vázající vápník krev   MeSH
• resistin * krev   MeSH
• studie případů a kontrol MeSH
• těhotenství MeSH
• Check Tag
• dospělí MeSH
• lidé MeSH
• těhotenství MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• adipokiny MeSH
• biologické markery * MeSH
• DNA vazebné proteiny MeSH
• krevní glukóza MeSH
• NUCB2 protein, human MeSH Prohlížeč
• nukleobindiny * MeSH
• plazmatické proteiny vázající retinol * MeSH
• proteiny nervové tkáně MeSH
• proteiny vázající vápník MeSH
• RBP4 protein, human MeSH Prohlížeč
• resistin * MeSH
• RETN protein, human MeSH Prohlížeč

BACKGROUND: Adipose tissue is significantly involved in inflammatory bowel disease (IBD). Vitamin D can affect both adipogenesis and inflammation. The aim of this study was to compare the production of selected adipokines, potentially involved in the pathogenesis of IBD - adiponectin, resistin, retinol binding protein 4 (RBP-4), adipocyte fatty acid binding protein and nesfatin-1 in children with IBD according to the presence of 25-hydroxyvitamin D (25(OH)D) deficiency. METHODS: The study was conducted as a case-control study in pediatric patients with IBD and healthy children of the same sex and age. In addition to adipokines and 25(OH)D, anthropometric parameters, markers of inflammation and disease activity were assessed in all participants. RESULTS: Children with IBD had significantly higher resistin levels regardless of 25(OH)D levels. IBD patients with 25(OH)D deficiency only had significantly lower RBP-4 compared to healthy controls and also compared to IBD patients without 25(OH)D deficiency. No other significant differences in adipokines were found in children with IBD with or without 25(OH)D deficiency. 25(OH)D levels in IBD patients corelated with RBP-4 only, and did not correlate with other adipokines. CONCLUSIONS: Whether the lower RBP-4 levels in the 25(OH)D-deficient group of IBD patients directly reflect vitamin D deficiency remains uncertain. The production of other adipokines does not appear to be directly related to vitamin D deficiency.

• Klíčová slova
• 25-hydroxyvitamin D, Adipocyte fatty acid binding protein, Adiponectin, Inflammatory bowel disease, Nesfatin-1, Resistin, Retinol-binding protein 4,
• MeSH
• adipokiny * krev   MeSH
• adiponektin krev   nedostatek   MeSH
• biologické markery krev   MeSH
• dítě MeSH
• DNA vazebné proteiny krev   MeSH
• idiopatické střevní záněty krev   komplikace   MeSH
• lidé MeSH
• mladiství MeSH
• nedostatek vitaminu D * komplikace   krev   MeSH
• nukleobindiny krev   MeSH
• plazmatické proteiny vázající retinol metabolismus   analýza   MeSH
• proteiny vázající mastné kyseliny krev   MeSH
• proteiny vázající vápník krev   MeSH
• resistin krev   MeSH
• studie případů a kontrol MeSH
• vitamin D * krev   analogy a deriváty   MeSH
• Check Tag
• dítě MeSH
• lidé MeSH
• mladiství MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• 25-hydroxyvitamin D MeSH Prohlížeč
• adipokiny * MeSH
• adiponektin MeSH
• biologické markery MeSH
• DNA vazebné proteiny MeSH
• FABP4 protein, human MeSH Prohlížeč
• NUCB2 protein, human MeSH Prohlížeč
• nukleobindiny MeSH
• plazmatické proteiny vázající retinol MeSH
• proteiny vázající mastné kyseliny MeSH
• proteiny vázající vápník MeSH
• RBP4 protein, human MeSH Prohlížeč
• resistin MeSH
• vitamin D * MeSH

BACKGROUND AND AIMS: Matrix Gla protein (MGP) is a natural inhibitor of vascular calcification critically dependent on circulating vitamin K status. Growth differentiation factor 15 (GDF-15) is a regulatory cytokine mainly of the inflammatory and angiogenesis pathways, but potentially also involved in bone mineralization. We sought to determine whether these two circulating biomarkers jointly influenced morbidity and mortality risk in patients with chronic coronary heart disease (CHD). METHODS AND RESULTS: 894 patients ≥6 months after myocardial infarction and/or coronary revascularization at baseline were followed in a prospective study. All-cause and cardiovascular mortality, non-fatal cardiovascular events (myocardial infarction, stroke, any revascularization), and hospitalization for heart failure (HF) were followed as outcomes. Desphospho-uncarboxylated MGP (dp-ucMGP) was used as a biomarker of vitamin K status. Both, increased concentrations of dp-ucMGP (≥884 pmol/L) and GDF-15 (≥1339 pg/mL) were identified as independent predictors of 5-year all-cause or cardiovascular mortality. However, their coincidence further increased mortality risk. The highest risk was observed in patients with high dp-ucMGP plus high GDF-15, not only when compared with those with "normal" concentrations of both biomarkers [HR 5.51 (95% CI 2.91-10.44), p < 0.0001 and 6.79 (95% CI 3.06-15.08), p < 0.0001 for all-cause and cardiovascular mortality, respectively], but even when compared with patients with only one factor increased. This pattern was less convincing with non-fatal cardiovascular events or hospitalization for HF. CONCLUSIONS: The individual coincidence of low vitamin K status (high dp-ucMGP) and high GDF-15 expression predicts poor survival of stable CHD patients.

• Klíčová slova
• All-cause death, Cardiovascular death, EUROASPIRE, Heart failure, Matrix γ-carboxyglutamate protein (MGP), Non-fatal cardiovascular events, dp-ucMGP,
• MeSH
• biologické markery krev   MeSH
• časové faktory MeSH
• chronická nemoc MeSH
• extracelulární matrix - proteiny krev   MeSH
• hodnocení rizik MeSH
• incidence MeSH
• koronární nemoc krev   diagnóza   mortalita   terapie   MeSH
• lidé středního věku MeSH
• lidé MeSH
• matrixový protein Gla MeSH
• nedostatek vitaminu D krev   diagnóza   mortalita   MeSH
• prognóza MeSH
• prospektivní studie MeSH
• proteiny vázající vápník krev   MeSH
• průřezové studie MeSH
• rizikové faktory MeSH
• růstový diferenciační faktor 15 krev   MeSH
• senioři MeSH
• upregulace MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Geografické názvy
• Česká republika epidemiologie   MeSH
• Názvy látek
• biologické markery MeSH
• extracelulární matrix - proteiny MeSH
• GDF15 protein, human MeSH Prohlížeč
• proteiny vázající vápník MeSH
• růstový diferenciační faktor 15 MeSH

OBJECTIVE: To review a literature about possible new blood serum gynecologic tumor markers, S100 proteins family, trefoil factor 3 and AIF-1. DESIGN: Literature review. SETTING: Department of Obstetrics and Gynecology, Faculty of Medicine, Palacky University and University Hospital in Olomouc. METHODS: Literature review of articles published in PubMed database till January 2019. RESULTS: The association of S100A2, S100A4, S100A6, S100A7, S100A8, S100A9 and S100A11 with breast carcinoma has been demonstrated in the literature. The association of S100A2, S100A4, S100A6, S100A7A, S100A10, S100A14, S100A16, S100B, S100P (up-regulation associated with a lower survival) and S100A1, S100A13, S100A5, S100A13 and S100G proteins (up-regulation associated with a better survival) have been demonstrated in ovarian cancer patients. Cervical carcinoma has been shown to be associated with the S100A9 protein. TFF3 association with endometrial cancer, breast cancer (worse prognosis) and ovarian cancer (better prognosis) has been demonstrated. AIF-1 has been shown to increase expression in cervical cancer. CONCLUSION: Tumor markers can be a very useful tool for patient management when used appropriately. Further research in this area and the search for new tumor markers, including S100, TFF3 and AIF-1, are needed. In future studies, scientists should focus not only on one time point, but assess the trend of the tumor markers for a specific time axis.

• Klíčová slova
• AIF-1, S100, TFF3, oncogynecology, tumor markers,
• MeSH
• faktor TFF3 krev   MeSH
• lidé MeSH
• mikrofilamentové proteiny krev   MeSH
• nádorové biomarkery * MeSH
• nádory vaječníků * diagnóza   MeSH
• prognóza MeSH
• proteiny S100 krev   MeSH
• proteiny vázající vápník krev   MeSH
• Check Tag
• lidé MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• přehledy MeSH
• Názvy látek
• AIF1 protein, human MeSH Prohlížeč
• faktor TFF3 MeSH
• mikrofilamentové proteiny MeSH
• nádorové biomarkery * MeSH
• proteiny S100 MeSH
• proteiny vázající vápník MeSH
• TFF3 protein, human MeSH Prohlížeč

The aim of this study was to compare the levels of nesfatin-1 in healthy subjects with those in prediabetic and diabetic patients who have different glucose tolerance levels. Overall, 100 subjects were divided into 5 groups healthy control (C), impaired fasting glycemia (IFG), impaired glucose tolerance (IGT), metabolic syndrome (MS) and type 2 diabetes mellitus, (Type 2 DM). Glycated hemoglobin (HbA1c) assessed the glycemic control. Homeostasis model assessment of insulin resistance (HOMA-IR) was determined using computer analyses. Nesfatin-1 levels were measured using ELISA method. IFG and IGT (prediabetic groups) from MS and Type 2 DM (diabetic groups) differed significantly in HOMA-IR. The nesfatin-1 levels were lower, although not statistically significant, in IFG (0.937+/-0.03 ng/ml, p=0.07) and IGT (1.039+/-0.06 ng/ml, p=0.5) groups compared to healthy subjects (1.094+/-0.07 ng/ml). However, the nesfatin-1 levels were lower in patients with Type 2 DM (0.867+/-0.02 ng/ml, p=0.007) and MS (0.885+/-0.01 ng/ml, p=0.01) compared to healthy subjects. Nesfatin-1 levels were significantly lower in diabetic patients compared to healthy subjects. This study supports the role of insulin resistance in decreased nesfatin-1 levels in patients with Type 2 DM and MS.

• MeSH
• diabetes mellitus 2. typu krev   MeSH
• DNA vazebné proteiny krev   MeSH
• dospělí MeSH
• glukózový toleranční test * MeSH
• glykovaný hemoglobin analýza   MeSH
• inzulinová rezistence MeSH
• krevní glukóza analýza   metabolismus   MeSH
• lidé MeSH
• metabolický syndrom krev   MeSH
• nukleobindiny MeSH
• porucha glukózové tolerance krev   MeSH
• prediabetes krev   MeSH
• proteiny nervové tkáně krev   MeSH
• proteiny vázající vápník krev   MeSH
• zdraví dobrovolníci pro lékařské studie MeSH
• Check Tag
• dospělí MeSH
• lidé MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• DNA vazebné proteiny MeSH
• glykovaný hemoglobin MeSH
• krevní glukóza MeSH
• NUCB2 protein, human MeSH Prohlížeč
• nukleobindiny MeSH
• proteiny nervové tkáně MeSH
• proteiny vázající vápník MeSH

Matrix Gla protein (MGP), a natural inhibitor of calcification, strongly correlates with the extent of coronary calcification. Vitamin K is the essential cofactor for the activation of MGP. The nonphosphorylated-uncarboxylated isoform of MGP (dp-ucMGP) reflects the status of this vitamin. We investigated whether there is an association between dp-ucMGP and stiffness of elastic and muscular-type large arteries in a random sample from the general population. In a cross-sectional design, we analyzed 1087 subjects from the Czech post-MONICA study. Aortic and femoro-popliteal pulse wave velocities (PWVs) were measured using a Sphygmocor device. Dp-ucMGP concentrations were assessed in freshly frozen samples by enzyme-linked immunosorbent assay methods using the InaKtif MGP iSYS pre-commercial kit developed by IDS and VitaK. Aortic PWV significantly (P<0.0001) increased across the dp-ucMGP quartiles. After adjustment for all potential confounders, aortic PWV independently correlated with dp-ucMGP (with beta coefficient (s.d.) 11.61 (5.38) and P-value=0.031). In a categorized manner, subjects in the top quartile of dp-ucMGP (⩾ 671 pmol l(-1)) had a higher risk of elevated aortic PWV, with corresponding adjusted odds ratio (95% confidence interval) 1.73 (1.17-2.5). In contrast, no relation between dp-ucMGP and femoro-popliteal PWV was found. In conclusion, increased dp-ucMGP, which is a circulating biomarker of vitamin K status and vascular calcification, is independently associated with aortic stiffness, but not with stiffness of distal muscular-type arteries.

• MeSH
• analýza pulzové vlny MeSH
• biologické markery krev   MeSH
• dospělí MeSH
• ELISA MeSH
• extracelulární matrix - proteiny krev   MeSH
• fosforylace MeSH
• lidé středního věku MeSH
• lidé MeSH
• lineární modely MeSH
• logistické modely MeSH
• matrixový protein Gla MeSH
• multivariační analýza MeSH
• nemoci aorty krev   diagnóza   patofyziologie   MeSH
• odds ratio MeSH
• onemocnění periferních arterií krev   diagnóza   patofyziologie   MeSH
• proteiny vázající vápník krev   MeSH
• průřezové studie MeSH
• rizikové faktory MeSH
• senioři MeSH
• tuhost cévní stěny * MeSH
• upregulace MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Geografické názvy
• Česká republika MeSH
• Názvy látek
• biologické markery MeSH
• extracelulární matrix - proteiny MeSH
• proteiny vázající vápník MeSH

BACKGROUND: Matrix Gla protein (MGP) is a natural inhibitor of tissue calcification. In a previous study, we observed the positive association between abnormal concentrations of uncarboxylated MGP species and increased mortality risk in stable vascular patients. We explore whether co-incidence of abnormal status of uncarboxylated MPG and heart failure (HF) affects the mortality risk. METHODS: We examined 799 patients (mean age 65.1 years) with stable vascular disease and followed them in a prospective study. Both, desphospho-uncarboxylated and total uncarboxylated MGP (dp-ucMGP or t-ucMGP) were quantified by pre-commercial ELISA assays. RESULTS: Elevated (>100 ng/L) circulating brain natriuretic peptide (BNP) and abnormal status of plasma uncarboxylated MGP species (i.e.: dp-ucMGP ≥ 977 pmol/L or t-ucMGP ≤ 2825 nmol/L) were all identified as robust predictors of all-cause 5-year mortality. However, their co-incidence represented a substantial additional risk. We observed the highest mortality risk in patients with elevated BNP plus high dp-ucMGP compared to those with normal BNP plus low dp-ucMGP; fully adjusted HRR's were 4.86 (3.15-7.49). Likewise, the risk was increased when compared with patients with elevated BNP plus low dp-ucMGP; HRR 2.57 (1.60-4.10). Similar result we observed when co-incidence of elevated BNP and low t-ucMGP was analyzed [corresponding HRR's were 4.16 (2.62-6.61) and 1.96 (1.24-3.12)]. CONCLUSIONS: The concomitant abnormality of uncarboxylated MGP and mild elevation of BNP leads in chronic patients with vascular disease to about two-fold increase of the relative mortality risk. We hypothesize that abnormal homeostasis of MGP is involved in the pathophysiology of HF.

• Klíčová slova
• Atherovascular disease, Heart failure, Matrix γ-carboxyl glutamate protein (MGP), Mortality, dp-ucMGP, t-ucMGP,
• MeSH
• biologické markery krev   MeSH
• extracelulární matrix - proteiny krev   MeSH
• hodnocení rizik * MeSH
• kalcinóza MeSH
• lidé MeSH
• matrixový protein Gla MeSH
• míra přežití trendy   MeSH
• následné studie MeSH
• nemoci cév krev   komplikace   mortalita   MeSH
• prospektivní studie MeSH
• proteiny vázající vápník krev   MeSH
• rizikové faktory MeSH
• senioři MeSH
• srdeční selhání krev   komplikace   mortalita   MeSH
• vitamin K MeSH
• Check Tag
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• multicentrická studie MeSH
• práce podpořená grantem MeSH
• Geografické názvy
• Česká republika epidemiologie   MeSH
• Názvy látek
• biologické markery MeSH
• extracelulární matrix - proteiny MeSH
• proteiny vázající vápník MeSH
• vitamin K MeSH

BACKGROUND: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is independently associated with cardiovascular risk, probably via inflammatory activity in sclerotic plaque. We speculated whether Lp-PLA2 has a role in the aetiology of vascular calcifications, estimated from circulating uncarboxylated matrix Gla protein (MGP) species and whether we could find a potential interaction of Lp-PLA2 and MGP in terms of mortality. MATERIALS AND METHODS: We examined 798 patients (mean age 65.1 years) with stable vascular disease and followed them in a prospective study. Both, desphospho-uncarboxylated and total MGP (dp-ucMGP or t-ucMGP) were quantified by pre-commercial ELISA assays, developed by VitaK (Maastricht, The Netherland) RESULTS: Lp-PLA2 activity was independently positively associated with desphospho-uncarboxylated MGP (dp-ucMGP) [β coeff = 0.098, p=0.006]. 1SD of Lp-PLA2 activity was associated with 37% increased risk (p=0.001) of elevated dp-ucMGP (≥977 pmol/L, top quartile). In the Cox proportional hazard model adjusted for conventional risk factors, the patients in the highest quartile of dp-ucMGP or lowest quintile of total-uncarboxylated ucMGP (<2660 nmol/L) had higher risk of all-cause mortality [HRR 2.79 (95% CI 1.97-3.94) and HRR 1.69 (95% CI 1.18-2.42), respectively]. We observed no effect of high Lp-PLA2 activity (≥195 nmol/min/mL) on total mortality. CONCLUSIONS: We assume that Lp-PLA2 is involved in vascular calcification and that dp-ucMGP is a more appropriate biomarker of residual risk than Lp-PLA2 itself.

• Klíčová slova
• Coronary heart disease, Euroaspire, Lipoprotein-associated phospholipaseA(2), Matrix Gla protein, Mortality risk, Stroke,
• MeSH
• 1-alkyl-2-acetylglycerofosfocholinesterasa krev   MeSH
• analýza přežití MeSH
• biologické markery krev   MeSH
• extracelulární matrix - proteiny krev   MeSH
• kardiovaskulární nemoci krev   mortalita   MeSH
• lidé středního věku MeSH
• lidé MeSH
• matrixový protein Gla MeSH
• proporcionální rizikové modely MeSH
• prospektivní studie MeSH
• proteiny vázající vápník krev   MeSH
• rizikové faktory MeSH
• senioři MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Geografické názvy
• Nizozemsko MeSH
• Názvy látek
• 1-alkyl-2-acetylglycerofosfocholinesterasa MeSH
• biologické markery MeSH
• extracelulární matrix - proteiny MeSH
• proteiny vázající vápník MeSH

BACKGROUND: Vitamin K is the essential co-factor for activation of matrix Gla-protein (MGP), the natural inhibitor of tissue calcification. Biologically inactive, desphospho-uncarboxylated MGP (dp-ucMGP) is a marker of vascular vitamin K status and is described to predict mortality in patients with heart failure and aortic stenosis. We hypothesized that increased dp-ucMGP might be associated with mortality risk in clinically stable patients with chronic vascular disease. MATERIALS AND METHODS: We examined 799 patients (mean age 65.1 ± 9.3 years) who suffered from myocardial infarction, coronary revascularization or first ischemic stroke (pooled Czech samples of EUROASPIRE III and EUROASPIRE-stroke surveys), and followed them in a prospective cohort study. To estimate the 5-year all-cause and cardiovascular mortality we ascertained vital status and declared cause of death. Circulating dp-ucMGP and desphospho-carboxylated MGP (dp-cMGP) were measured by ELISA methods (IDS and VitaK). RESULTS: During a median follow-up of 2050 days (5.6 years) 159 patients died. In the fully adjusted multivariate Cox proportional hazard model, the patients in the highest quartile of dp-ucMGP (≥ 977 pmol/L) had higher risk of all-cause and cardiovascular 5-year mortality [HRR 1.89 (95% CI, 1.32-2.72) and 1.88 (95% CI, 1.22-2.90)], respectively. Corresponding HRR for dp-cMGP were 1.76 (95% CI, 1.18-2.61) and 1.79 (95% CI, 1.12-2.57). CONCLUSIONS: In patients with overt vascular disease, circulating dp-ucMGP and dp-cMGP were independently associated with the risk of all-cause and cardiovascular mortality. Since published results are conflicting regarding the dp-cMGP, we propose only circulating dp-ucMGP as a potential biomarker for assessment of additive cardiovascular risk.

• Klíčová slova
• Coronary heart disease, Dp-cMGP, Dp-ucMGP, EUROASPIRE, Matrix Gla-protein, Mortality, Secondary prevention, Stroke,
• MeSH
• biologické markery krev   MeSH
• cévní mozková příhoda krev   mortalita   MeSH
• ELISA MeSH
• extracelulární matrix - proteiny krev   chemie   MeSH
• infarkt myokardu krev   mortalita   MeSH
• ischemická choroba srdeční krev   mortalita   MeSH
• Kaplanův-Meierův odhad MeSH
• kardiovaskulární nemoci krev   diagnóza   MeSH
• lidé středního věku MeSH
• lidé MeSH
• matrixový protein Gla MeSH
• nemoci cév krev   mortalita   MeSH
• proporcionální rizikové modely MeSH
• prospektivní studie MeSH
• proteiny vázající vápník krev   chemie   MeSH
• regresní analýza MeSH
• revaskularizace myokardu mortalita   MeSH
• senioři MeSH
• vitamin K metabolismus   MeSH
• výsledek terapie MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Názvy látek
• biologické markery MeSH
• extracelulární matrix - proteiny MeSH
• proteiny vázající vápník MeSH
• vitamin K MeSH

BACKGROUND: Predicting the long-term outcome after traumatic brain injury (TBI) is an important component of treatment strategy. Despite dramatically improved emergency management of TBI and apparent clinical recovery, most patients with TBI still may have long-term central nervous system (CNS) impairment. METHODS: Sixty-three patients with TBI were enrolled into the prospective study. Venous blood samples were taken at admission and every 24 h for a maximum of 6 consecutive days. Serum concentrations of the biomarkers S100B, neuron-specific enolase (NSE), GFAP, NF-H, secretagogin and Hsp70 were quantified immuno-luminometrically or by enzyme-linked immunosorbent assay. The outcome was evaluated 6 months after TBI using the Glasgow Outcome Scale (GOS) in all patients. RESULTS: The S100B levels in patients with worse outcome (GOS 4 or death) were already significantly higher at D0 (p < 0.001; p = 0.002). NSE levels were significantly higher in patients who died or had worse outcomes (p < 0.001; p = 0.003). Patients who had worse outcomes (GOS) or died had higher GFAP values (p < 0.001; p < 0.001), but their dynamics were similar over the same period. NF-H grew significantly faster in patients who had a worse GOS or died (p < 0.001; p = 0.001). CONCLUSIONS: Although further prospective study is warranted, these findings suggest that levels of biomarkers correlate with mortality and may be useful as predictors of outcome in children with TBI.

• MeSH
• biologické markery krev   MeSH
• dítě MeSH
• gliový fibrilární kyselý protein krev   MeSH
• kojenec MeSH
• lidé MeSH
• mladiství MeSH
• mladý dospělý MeSH
• neurofilamentové proteiny krev   MeSH
• neurotrofní faktory krev   MeSH
• novorozenec MeSH
• poranění mozku krev   mortalita   terapie   MeSH
• prediktivní hodnota testů MeSH
• předškolní dítě MeSH
• prospektivní studie MeSH
• proteiny S100 krev   MeSH
• proteiny tepelného šoku HSP70 krev   MeSH
• proteiny vázající vápník krev   MeSH
• S-100 kalcium vázající protein G, podjednotka beta MeSH
• secretagoginy MeSH
• transportní proteiny krev   MeSH
• výsledek terapie MeSH
• Check Tag
• dítě MeSH
• kojenec MeSH
• lidé MeSH
• mladiství MeSH
• mladý dospělý MeSH
• mužské pohlaví MeSH
• novorozenec MeSH
• předškolní dítě MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• biologické markery MeSH
• gliový fibrilární kyselý protein MeSH
• neurofilament protein H MeSH Prohlížeč
• neurofilamentové proteiny MeSH
• neurotrofní faktory MeSH
• NSMCE1 protein, human MeSH Prohlížeč
• proteiny S100 MeSH
• proteiny tepelného šoku HSP70 MeSH
• proteiny vázající vápník MeSH
• S-100 kalcium vázající protein G, podjednotka beta MeSH
• S100B protein, human MeSH Prohlížeč
• SCGN protein, human MeSH Prohlížeč
• secretagoginy MeSH
• transportní proteiny MeSH